NPPA Fixes Retail Price Of 12 Formulations, Details

Written by Dr. Divya Colin Published On 2023-01-14T16:00:50+05:30 | Updated On 18 Oct 2023 5:00 PM IST

NPPA Fixes Retail Price Of 12 Formulations, Details

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizers, Government of India has fixed the retail price of 12 formulations including Non-steroidal anti-inflammatory drugs (NSAIDs), antidiabetic drugs, antihypertensive drugs and others.

This came in line with the decision of the 107th authority meeting dated 11.01.2023, where the Authority discussed new drug applications for price fixation, under the Drug ( Price Control) Order 2013.

These include Akum Pharmaceuticals/Apex Laboratories Glimepiride, Voglibose & Metformin (Extended- release) tablets, Alicons Pharmaceuticals/ Dale Laboratories Paracetamol, Phenylephrine Hydrochloride, Diphenhydramine Hydrochloride and Caffeine Tablets, Akums Pharmaceutical's/Torrent Pharma's Paracetamol, Phenylephrine and Chlorpheniramine Tablets, Pure & Cure Pharmaceuticals/ Intas Pharmaceuticals Desvenlafaxine Extended Release and Clonazepam Tablets, Ravenbhel Healthcare/Intas Pharmaceuticals Thiocolchicoside, Aceclofenac and Paracetamol Tablet, Ravenbhel Healthcare/Abbott Healthcare Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets, Pure & Cure/ Zydus Pharma's Montelukast and Acebrophylline (SR) Tablets, Pure & Cure/ Torrent Pharma's Pantoprazole Tablets and others.

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Glimepiride, Voglibose & Metformin (Extended- release) tablets	Each uncoated bilayered tablet contains: Glimepiride IP 2mg, Voglibose IP 0.2mg Metformin Hydrochloride IP 500mg (as Extended- release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Apex Laboratories Pvt. Ltd.	13.83
2.	Paracetamol, Phenylephrine Hydrochloride, Diphenhydrami ne Hydrochloride and Caffeine Tablets	Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 5mg Diphenhydramine Hydrochloride IP 25mg Caffeine (Anhydrous) IP 30mg	1 Tablet	M/s Alicon Pharmaceuticals Pvt. Ltd. / M/s Dales Laboratories Pvt. Ltd.	2.76
3.	Paracetamol, Phenylephrine and Chlorphenirami ne Tablets	Each film coated tablet contains: Paracetamol IP 500mg Phenylephrine Hydrochloride IP 10mg Chlorpheniramine maleate IP 2mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Limited	4.36
4.	Desvenlafaxine Extended Release and	Each uncoated bilayered tablet contains:	1 Tablet	M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Intas	13.24

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	Clonazepam Tablets	Desvenlafaxine Succinate USP eq. to Desvenlafaxine 50mg (As extended-release form) Clonazepam IP 0.25mg		Pharmaceuticals Ltd.
5.	Thiocolchicosid e, Aceclofenac and Paracetamol Tablet	Each film coated tablet contains: Thiocolchicoside IP 8mg Aceclofenac IP 100 mg Paracetamol IP 325 mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Intas Pharmaceuticals Ltd.	24.78
6.	Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets	Each film coated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 12.5mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as Extended release) 25mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	10.90
7.	Telmisartan, Chlorthalidone & Metoprolol (ER) Tablets	Each film coated bilayered tablet contains: Telmisartan IP 40mg Chlorthalidone IP 12.5mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as Extended release) 50mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	13.15
8.	Rosuvastatin & Clopidogrel Capsules	Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsul e	M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd.	13.66
9.	Rosuvastatin & Clopidogrel Capsules	Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsul e	M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd.	16.96

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
10.	Rosuvastatin, Clopidogrel & Aspirin Capsule	Each Hard gelatin capsule cotains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg Aspirin IP 75mg	1 Capsul e	M/s Windlas Biotech Limited. / M/s Modi- Mundipharma Pvt. Ltd.	20.53
11.	Montelukast and Acebrophylline (SR) Tablets	Each uncoated bilayered tablet contains: Montelukast Sodium IP eq. to Montelukast 10mg Acebrophylline 200mg (As Sustained release)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Zydus Healthcare Limited	16.12
12.	Pantoprazole Tablets IP	Each enteric coated tablet contains: Pantoprazole Sodium IP eq. to Pantoprazole 20mg	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Limited	6.68

The notice further added:

(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above-mentioned retail price is applicable only to the individual manufacturer /marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of the retail price of such formulation as specified in column(2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.

Also Read:NPPA Fixes Retail Price Of 36 Formulations, Details

npparetail priceprice fixationmetforminglimepiridezydustorrentAbbottakums drug

Dr. Divya Colin

Doctor of Pharmacy

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.